Eye Drops Offer New Hope for Millions Needing Reading Glasses

Key Takeaways

1. Introduction of Vizz Eye Drops: Vizz eye drops by Lenz Therapeutics are a new FDA-approved treatment for presbyopia, using aceclidine to improve near vision.

2. Longer Duration of Effect: Vizz drops start working in about 30 minutes and last up to 10 hours, offering a longer effect compared to similar products like Vuity.

3. Clinical Trial Success: FDA approval was based on three Phase III trials with over 680 participants, showing significant improvement in near vision and good tolerability.

4. Target Demographic: Vizz is most effective for individuals aged 45 to 55 in the early stages of presbyopia, but effectiveness decreases in dim lighting.

5. Market Launch and Pricing: Initial samples will be available to doctors in October 2025, with a full market launch expected by the end of that year; pricing will likely be similar to Vuity, which costs around $100 monthly.

Presbyopia, or age-related farsightedness, impacts almost everyone starting in their mid-40s, though it can actually begin earlier for some. Traditionally, people have depended on reading glasses or contact lenses, while others have chosen surgical options. Recently, the US Food and Drug Administration (FDA) has given the green light for a new alternative treatment.

A New Hope: Vizz Eye Drops

With the introduction of Vizz eye drops by Lenz Therapeutics, many could find relief from needing reading glasses. These drops contain aceclidine as their active ingredient, which works by narrowing the pupil to create a pinhole effect, making vision clearer. The company states that the drops begin to work in about 30 minutes and can last for up to 10 hours, which is much longer compared to similar products like Vuity from AbbVie/Allergan, which normally last about 4 to 6 hours. One of Vizz’s key benefits is that, unlike Vuity, it doesn’t affect distance vision.

Clinical Trials and Tolerability

The FDA’s approval was founded on three Phase III trials that included over 680 participants and more than 30,000 treatment days. Results from the CLARITY-1 and CLARITY-2 studies showed a significant improvement in near vision, and the long-term CLARITY-3 trial demonstrated good tolerability over a six-month period. The most frequent side effects were mild and temporary, such as eye irritation, decreased vision in low-light situations, headaches, and redness.

Effectiveness and Market Launch

There is no exact guideline on the diopter range where Vizz is most beneficial. An ophthalmologist on Reddit mentioned that these drops tend to be most effective in the early stages of presbyopia, usually for individuals aged 45 to 55. They also indicated that the effect is reduced in dim lighting, as pupils remain constricted.

Results from the studies suggest that Vizz could help many avoid wearing glasses. In the US, initial samples are set to be distributed to doctors in October 2025, with a market launch anticipated by the end of that year. A timeline for Europe remains unclear, where the product will be sold through partner Théa. However, cost may present a challenge: Vuity, which is currently only available in the US, costs as much as $100 monthly and is not insured, and similar pricing is expected for Vizz.

Source:
Link